Zobrazeno 1 - 10
of 339
pro vyhledávání: '"Zeidan, Am"'
Publikováno v:
Cancer Management and Research, Vol Volume 13, Pp 645-657 (2021)
Russell Lewis, Jan Philipp Bewersdorf, Amer M Zeidan Department of Medicine, Section of Hematology, Yale University, New Haven, CT, USACorrespondence: Amer M ZeidanDepartment of Medicine, Section of Hematology, Smilow Cancer Center at Yale New Haven
Externí odkaz:
https://doaj.org/article/0a985db87df14bdfab4711b5dc5c0368
Publikováno v:
Cancer Management and Research, Vol Volume 11, Pp 10777-10790 (2019)
Jan Philipp Bewersdorf,1 Sara Mohamed Jaszczur,2 Salma Afifi,2 Jennifer C Zhao,2 Amer M Zeidan1,3 1Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; 2Department of Pharmacy, Yale New Haven Hospital,
Externí odkaz:
https://doaj.org/article/e58b0f6e7f1545038ba16aaaaa6533ef
Publikováno v:
Journal of Blood Medicine, Vol Volume 9, Pp 67-74 (2018)
Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USAAbstract: The improvement in outcomes of adult patients with acute lymphoblastic leukemia
Externí odkaz:
https://doaj.org/article/8cda8204d2364c34a15a1e3618210b0e
Autor:
Sekeres, MA, Schuster, M, Joris, M, Krauter, J, Maertens, J, Breems, D, Gyan, E, Kovacsovics, T, Verma, A, Vyas, P, Wang, ES, Ching, K, O'Brien, T, Gallo Stampino, C, Ma, WW, Kudla, A, Chan, G, Zeidan, AM
This phase 1b study evaluated glasdegib (100mg once daily) + azacitidine in adults with newly diagnosed acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML) who were ineligible for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c8f36ca71795a291853636c8a046d8
https://doi.org/10.1007/s00277-022-04853-4
https://doi.org/10.1007/s00277-022-04853-4
Publikováno v:
Journal of Blood Medicine, Vol 2015, Iss default, Pp 1-16 (2014)
Abdallah Abou Zahr,1 Ehab Saad Aldin,2 Rami S Komrokji,3 Amer M Zeidan4 1Section of Hematology/Oncology, Department of Internal Medicine, Mount Sinai Beth Israel, New York City, New York, NY, 2Department of Internal Medicine, Medstar Good Samaritan H
Externí odkaz:
https://doaj.org/article/841cde409b324735a4c48a53b37a3b61
Autor:
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G
Publikováno v:
Blood Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune checkpoint inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d7393970984e7951f0067f76983b56ac
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16525
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16525
Autor:
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR
Publikováno v:
Blood Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with azacitidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::5c6149993caa366cacfab790ddcd6dcf
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16526
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16526
Autor:
Zeidan, Am, Boss, Iw, Beach, Cl, Copeland, Wb, Thompson, Eg, Fox, Ba, Hasle, Ve, Ogasawara, K, Cavenagh, J, Silverman, Lr, Voso, Mt, Hellmann, A, Tormo, M, O'Connor, T, Previtali, A, Rose, S, Garcia-Manero, G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3667::16f9d2ffd10784b157b49abd9bd5c948
http://hdl.handle.net/2108/293123
http://hdl.handle.net/2108/293123
Autor:
DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e653953194069f3873e8d524900543ed
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15061
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15061
Autor:
Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, RM, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, AT, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS, Stone, RM, Mascarenhas, J
Publikováno v:
LANCET HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::aad6dbb5caa5579516dbfbb5aa2dcba5
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12638
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12638